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jects from the analysis because they are on
statins effectively excludes the majority of
patients undergoing coronary surgery. We
report that clopidogrel, unlike aspirin, did
not inhibit platelet aggregation in the first 5
postoperative days, a result that is applica-
ble to the wider population of patients ir-
respective of the eventual outcome of the
drug interaction debate.
Little consideration has been given to
the suggestion of excluding nonresponders
and low responders from the analysis. If we
did that for any arm of any trial only the
favorable responders would be left, giving
the false impression of treatment efficacy.
It is plausible that increasing the dose of
clopidogrel may increase antiplatelet ef-
fects in similar conditions (but this should
not be assumed). However, the current rec-
ommended dose is 75 mg per day, and a
loading dose of clopidogrel is only indi-
cated in unstable angina (300 mg single
loading dose).3 This information is consis-
tent with the product information sheet is-
sued by Sanofi-Synthelabo (New York,
NY).
Our aim was to report the results of an
intention-to-treat randomized clinical trial,
using approved drug doses, with findings
that can be generalized to the wide popu-
lation undergoing coronary surgery, not to
manipulate analyses to favor any particular
arm.
Eric Lim
Papworth Hospital
Cambridge
United Kingdom
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Clinical efficacy of retrograde
coronary sinus perfusion in off-pump
surgery
To the Editor:
I read with great interest the article by
Castella and Buckberg1on retrograde coro-
nary sinus perfusion in off-pump surgery.
My colleagues and I have been constantly
stimulated by the pioneering work of Dr
Buckberg on myocardial preservation. It is
indeed very gratifying and encouraging to
know that the technique we2 have been
using regularly since September 1997 to
perform off-pump coronary artery bypass
grafting (OPCABG) with no ischemia dur-
ing periods of construction of the distal
anastomosis has been proven by the very
elegant work of Castella and Buckberg1 to
be effective in reducing systolic and dia-
stolic dysfunction during periods of coro-
nary occlusion. In our technique, after mid-
sternotomy a retrograde coronary sinus
catheter is inserted and connected to an
antegrade cannula in the ascending aorta.2
Perfusion is now allowed through this route
from the aorta to the coronary sinus, on-
ward through the capillaries to the myocar-
dium, and out through the arterioles at the
site of ischemia. There is ample proof that
ischemia is relieved as evidenced by the
following facts: (1) reversion of electro-
cardiographic changes of ischemia, (2) vig-
orous backbleeding of dark blood on tem-
porary release of the distal snare after
arteriotomy, and (3) a good oxygen extrac-
tion ratio across the myocardium calculated
by sampling blood from the antegrade can-
nula and from the arteriotomy.3
Figure 1. Technique of retrograde perfusion during combined carotid endarterectomy and
coronary artery bypass grafting. A, Antegrade cardioplegia cannula; R, retrograde coro-
nary sinus cannula; S, stenosed coronary artery; CEA, carotid endarterectomy in progress;
P, pressure monitoring line.
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We have now gone one step further and
use the method of active retroperfusion, using
the driving pressure and oxygen of the aortic
blood to perfuse areas of pre-existing acute
ischemia. In grossly unstable patients with
critical left anterior descending or left main
stenosis, we have observed that retrograde
coronary sinus perfusion reverses electrocar-
diographic changes, reduces pulmonary ar-
tery pressures, immediately improves cardiac
contractility, and improves cardiac output
(unpublished data). This gives time to harvest
appropriate conduits, to perform any con-
comitant extracardiac procedure, and avoids
“crashing” on cardiopulmonary bypass. One
75-year-old patient with vascular disease and
cardiogenic shock was on preoperative intra-
aortic balloon counterpulsation and preoper-
ative ventilation, with associated critical bi-
lateral extracranial symptomatic internal
carotid artery disease. Retrograde coronary
sinus perfusion allowed stabilization of the
cardiac status and gave time to perform a
carotid endarterectomy (Figure 1) fol-
lowed by an OPCABG, with a good out-
come.4
My technique is a combination of pres-
sure-controlled intermittent coronary sinus
occlusion and arterial retroperfusion of the
coronary sinus. Possibly a better method
physiologically may well be a combination
of synchronized retroperfusion and pres-
sure-controlled intermittent coronary sinus
occlusion. There is a great potential for
developing catheters that could be inflated
in the coronary sinus 6 times per minute,5
but while that happens I would recommend
my simple technique of retrograde perfu-
sion as a useful tool in the armamentarium
of the cardiac surgeon for elective OP-
CABG as also for the acutely ischemic
patient, in whom one gains some time and
possibly avoids the institution of cardiopul-
monary bypass. I would wholeheartedly
agree with Lazar5 that a backward tech-
nique can still achieve forward progress.
Harinder Singh Bedi, MCh
Executive Director and Chairman,
Cardiac Sciences
Sigma New Life Heart Institute
562, Phase 1
Mohali—160055
Punjab, India
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What is the true (unbiased)
percentage freedom from atrial
fibrillation at 6 months after the
modified Cox maze procedure using
bipolar radiofrequency energy?
To the Editor:
We read with interest the article by Gaynor
and associates1 concerning the results of
their prospective study of a consecutive
group of 40 patients with 100% follow-up
in which they reported a 91% freedom
from atrial fibrillation (AF) at 6 months.
However, the denominator of patients at
6 months was only 23; therefore, 43% (17
patients) remained unaccounted for at that
time point (presumably because they had
not yet reached the 6-month interval). The
authors used “at last follow-up” analysis to
declare 100% follow-up, but usually the
percentage follow-up is reported as the
number of patients at the last time point (in
studies with a pre-planned stopping point).
In this case, some would consider the result
of reporting only 23 of the 40 potential
patients to have the same degree of inac-
curacy as a loss to follow-up of 17 of 40
(43%).
A 91% freedom from AF at 6 months is
based on the assumption that the remaining
17 patients will not alter this percentage
when followed up to 6 months (note the
71% freedom from AF in the first month
with 38 patients). However, in an ex-
tremely pessimistic situation (should AF
subsequently develop in all 17 patients),
the results could potentially be 21/40
(53%) freedom from AF at 6 months and
11/40 (28%) freedom from AF and antiar-
rhythmic medication at 6 months. We do
acknowledge, however, that the true esti-
mate would probably lie somewhere be-
tween the best- and worst-case scenarios.
Moreover, 10 (43%) of the 23 patients
were receiving antiarrhythmic medication
at 6 months. Unless the authors prescribed
prophylactic antiarrhythmic therapy, it
seems natural to assume that the 10 patients
were having AF up to and including the
6-month interval. The authors also in-
cluded 5 patients (13%) who were in par-
oxysmal AF at the start of the study, and 6
patients (15%) required pacemakers post-
operatively due to sick sinus syndrome.
Should freedom from AF be attributed to
surgery in these patients?
A Kaplan-Meier analysis would have
been more suitable to account for the un-
available/censored numbers that increased
from 2 to 7 to 17 by 6 months if (any) AF
was counted as evidence of an event (re-
gardless of subsequent rhythm). We note
that in this study, patients had different AF
status at different follow-up times (evident
from the increasing numerator between the
first and third months), and perhaps more
sophisticated methods needed to be em-
ployed (recurring time-to-event analysis) to
quantify the uncertainty in the estimation
of the time-dependent results.
In the same vein, Figure 6 in the manu-
script is somewhat misleading. The denom-
inator at the 4 time points decreased from
38 to 33 to 23; therefore, the apparent im-
provement could still be distorted by the
yet-to-be completed follow-up.
Bearing in mind the lower limit of the
confidence interval of 21/23 (95% confi-
dence interval, 72% to 99%), we respect-
fully express our reservations to the con-
clusions of this otherwise novel and
exciting modification of the Cox proce-
dure.
Eric Lim
Stephen Large
Papworth Hospital
Cambridge, United Kingdom
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